Ovarian Cancer

Radiologic Clinics of North America

Volumn 45, Issue 1, 2007, Pages 149-166

  Mironov, Svetlana ^a   Akin, Oguz ^a   Pandit Taskar, Neeta ^a   Hann, Lucy E ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ABDOMINAL HYSTERECTOMY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CAUSE OF DEATH; CLIMACTERIUM; COLON CANCER; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; DYSGERMINOMA; ENDOMETRIOSIS; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; GERM CELL TUMOR; GRANULOSA CELL TUMOR; HEMOPERITONEUM; HUMAN; MELANOMA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIECTOMY; OVARY; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PLEURA EFFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALPINGOOOPHORECTOMY; STOMACH CANCER; VIRILIZATION;

AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CHEMOTHERAPY, ADJUVANT; CONTRAST MEDIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 33845191963     PISSN: 00338389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rcl.2006.10.012     Document Type: Review

References (97)

1. Stat bite: Age-specific incidence and mortality rates for ovarian cancer, 1998-2002. J Natl Cancer Inst 98 8 (2006) 511
2. Jung S.E., Lee J.M., Rha S.E., et al. CT and MR imaging of ovarian tumors with emphasis on differential diagnosis. Radiographics 22 6 (2002) 1305-1325
3. Wu T.T., Coakley F.V., Qayyum A., et al. Magnetic resonance imaging of ovarian cancer arising in endometriomas. J Comput Assist Tomogr 28 6 (2004) 836-838
4. deSouza N.M., O'Neill R., McIndoe G.A., et al. Borderline tumors of the ovary: CT and MRI features and tumor markers in differentiation from stage I disease. AJR Am J Roentgenol 184 3 (2005) 999-1003
5. Exacoustos C., Romanini M.E., Rinaldo D., et al. Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol 25 1 (2005) 50-59
6. Jung S.E., Rha S.E., Lee J.M., et al. CT and MRI findings of sex cord-stromal tumor of the ovary. AJR Am J Roentgenol 185 1 (2005) 207-215
7. Kim S.H., and Kim S.H. Granulosa cell tumor of the ovary: common findings and unusual appearances on CT and MR. J Comput Assist Tomogr 26 5 (2002) 756-761
8. Brown D.L., Zou K.H., Tempany C.M., et al. Primary versus secondary ovarian malignancy: imaging findings of adnexal masses in the radiology diagnostic oncology group study. Radiology 219 1 (2001) 213-218
9. Ferrozzi F., Tognini G., Bova D., et al. Non-Hodgkin lymphomas of the ovaries: MR findings. J Comput Assist Tomogr 24 3 (2000) 416-420
10. Bourne T.H., Campbell S., Reynolds K.M., et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ 306 (1993) 1025-1029
11. Buys S.S., Partridge E., Greene M.H., et al. Ovarian cancer screening in the prostate, lung colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 193 (2005) 1630-1639
12. Campbell S., Royston P., Bhan V., et al. Novel screening strategies for early ovarian cancer by transabdominal ultrasonography. Br J Obstet Gynaecol 97 4 (1990) 304-311
13. Einhorn N., Bast R., Knapp R., et al. Long-term follow-up of the Stockholm screening study on ovarian cancer. Gynecol Oncol 79 (2000) 466-470
14. Jacobs I.J., Skates S.J., MacDonald N., et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353 9160 (1999) 1207-1210
15. Sato S., Yokoyama Y., Sakamoto T., et al. Usefulness of mass screening for ovarian carcinoma using transvaginal sonography. Cancer 89 (2000) 582-588
16. Stirling D., Evans G.R., Pichert G., et al. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics system. J Clin Oncol 23 (2005) 5588-5596
17. Tailor A., Bourne T.H., Campbell S., et al. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol 21 4 (2003) 378-385
18. Van Nagell Jr. J.R., DePriest P.D., Reedy M.B., et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 77 (2000) 350-356
19. Duffy M.J., Bonfrer J.M., Kulpa J., et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 15 5 (2005) 679-691
20. Hogg R., and Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 22 7 (2004) 1315-1327
21. Schmeler K.M., Lynch H.T., Chen L.M., et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354 3 (2006) 261-269
22. Taylor K., and Schwartz P.E. Cancer screening in a high risk population: a clinical trial. Ultrasound Med Biol 27 4 (2001) 461-466
23. Karlan B., Baldwin R.L., Lopez-Luevanos E., et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 180 4 (1999) 917-928
24. King M.C., Marks J.H., and Mandell J.B. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 5645 (2003) 643-646
25. Liede A., Karlan B.Y., Baldwin R., et al. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 20 6 (2002) 1570-1577
26. Struewing J.P., Hartge P., Wacholder S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336 20 (1997) 1401-1408
27. Dorum A., Heimdal K., Lovslett K., et al. Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet Gynecol Scand 78 10 (1999) 906-911
28. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 21 (2002) 1609-1615
29. Cohen L.S., Escobar P.F., Scharm C., et al. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 82 (2001) 40-48
30. Kinkel K., Hricak H., Ying Lu, et al. US characterization of ovarian masses: a meta-analysis. Radiology 217 (2000) 803-811
31. Kurjak A., Kupesic S., Sparac V., et al. Preoperative evaluation of pelvic tumors by Doppler and three-dimensional sonography. J Ultrasound Med 20 (2001) 829-840
32. Kurjak A., Kupesic S., Sparac V., et al. The detection of stage I ovarian cancer by three-dimensional sonography and power Doppler. Gynecol Oncol 90 2 (2003) 258-264
33. Funt S.A., and Hann L.E. Detection and characterization of adnexal masses. Radiol Clin North Am 40 3 (2002) 591-608
34. Jain K.A. Prospective evaluation of adnexal masses with endovaginal gray-scale and duplex and color Doppler US: Correlation with pathologic findings. Radiology 191 1 (1994) 63-67
35. Salem S., and Wilson S.R. Gynecologic ultrasound. In: Rumack C.M., Wilson S.R., Charboneau J.W., et al. (Eds). Diagnostic Ultrasound. 2nd edition (2005), Mosby, Philadelphia
36. Brown D.L., Doubilet P.M., Miller F.H., et al. Benign and malignant ovarian masses: selection of the most discriminating gray-scale and Doppler sonographic features. Radiology 208 (1998) 103-110
37. DiSantis D.J., Scatarige J.C., Kemp G., et al. A prospective evaluation of transvaginal sonography for detection of ovarian disease. AJR Am J Roentgenol 161 (1993) 91-94
38. Ferrazzi E., Zanetta G., Dordoni D., et al. Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study. Ultrasound Obstet Gynecol 10 (1997) 192-197
39. Kurjak A., and Predanic M. New scoring system for prediction of ovarian malignancy based on transvaginal color Doppler sonography. J Ultrasound Med 11 (1992) 631-638
40. Timor-Tritsch I.E., Lerner J.P., Monteagudo A., et al. Transvaginal ultrasonographic characterization of ovarian masses by means of color flow-directed Doppler measurements and a morphologic scoring system. Am J Obstet Gynecol 168 3 Pt 1 (1993) 909-913
41. Timmerman D., Schwarzler P., Collins W.P., et al. Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience. Ultrasound Obstet Gynecol 13 1 (1999) 11-16
42. Schelling M., Braun M., Kuhn W., et al. Combined transvaginal B-mode and color Doppler sonography for differential diagnosis of ovarian tumors: results of a multivariate logistic regression analysis. Gynecol Oncol 77 (2000) 78-86
43. Guerriero S., Alcazar J.L., Coccia M.E., et al. Complex pelvic mass as a target of evaluation of vessel distribution by color Doppler sonography for the diagnosis of adnexal malignancies: results of a mulitcenter European study. J Ultrasound Med 21 (2002) 1105-1111
44. Brown D.L., Frates M.C., Laing F.C., et al. Ovarian masses: can benign and malignant lesions be differentiated with color and pulsed Doppler US?. Radiology 190 2 (1994) 333-336
45. Hamper U.M., Sheth S., Abbas F.M., et al. Transvaginal color Doppler sonography of adnexal masses: differences in blood flow impedance in benign and malignant lesions. AJR Am J Roentgenol 160 6 (1993) 1225-1228
46. Levine D., Feldstein V.A., Babcook C.J., et al. Sonography of ovarian masses: poor sensitivity of resistive index for identifying malignant lesions. AJR Am J Roentgenol 162 6 (1994) 1355-1359
47. Salem S., White L.M., and Lai J. Doppler sonography of adnexal masses: the predictive value of the pulsatility index in benign and malignant disease. AJR Am J Roentgenol 163 5 (1994) 1147-1150
48. Valentin L. Prospective cross-validation of Doppler ultrasound examination and gray-scale ultrasound imaging for discrimination of benign and malignant pelvic masses. Ultrasound Obstet Gynecol 14 4 (1999) 273-283
49. Buy J.N., Ghossain M.A., Hugol D., et al. Characterization of adnexal masses: combination of color Doppler and conventional sonography compared with spectral Doppler analysis alone and conventional sonography alone. AJR Am J Roentgenol 166 2 (1996) 385-393
50. Wagner B., Buck J., Seidman J.D., et al. Ovarian epithelial neoplasms: radiologic-pathologic correlation. Radiographics 14 (1994) 1351-1374
51. Rieber A., Nussle K., Stohr I., et al. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histological findings. AJR Am J Roentgenol 177 1 (2001) 123-129
52. Halvorsen Jr. R.A., Panushka C., Oakley G.J., et al. Intraperitoneal contrast material improves the CT detection of peritoneal metastases. AJR Am J Roentgenol 157 1 (1991) 37-40
53. Komatsu T., Konishi I., Madai M., et al. Adnexal masses: Transvaginal US and gadolinium-enhanced MRI assessment of intratumoral structure. Radiology 198 (1996) 109-115
54. Funt S.A., and Hricak H. Ovarian malignancies. Top Magn Reson Imaging 14 4 (2003) 329-337
55. Jeong Y.Y., Outwater E.K., and Kang H.K. Imaging evaluation of ovarian masses. Radiographics 20 5 (2000) 1445-1470
56. Hricak H., Chen M., Coakley F.V., et al. Complex adnexal masses: detection and characterization with MR imaging-multivariate analysis. Radiology 214 1 (2000) 39-46
57. Sohaib S.A., Sahdev A., Van Trappen P., et al. Characterization of adnexal mass lesions on MR imaging. AJR Am J Roentgenol 180 5 (2003) 1297-1304
58. Kurtz A.B., Tsimikas J.V., Tempany C.M., et al. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis-report of the Radiology Diagnostic Oncology Group. Radiology 212 1 (1999) 19-27
59. Kinkel K., Lu Y., Mehdizade A., et al. Indeterminate ovarian mass at US: incremental value of second imaging test for characterization-meta-analysis and Bayesian analysis. Radiology 236 (2005) 85-94
60. Schwartz P.E. Cytoreductive surgery for the management of stage IV ovarian cancer. Gynecol Oncol 64 1 (1997) 1-3
61. Subhas N., Patel P.V., Pannu H.K., et al. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics 25 4 (2005) 1031-1043
62. Fenchel S., Grab D., Nuessle K., et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 223 3 (2002) 780-788
63. Grab D., Flock F., Stöhr I., et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 77 3 (2000) 454-459
64. Greene F., Page D., Fleming I., et al. AJCC cancer staging handbook. 6th edition (2002), Springer-Verlag, New York
65. Holloway B.J., Gore P.H., A'Hern R.P., et al. The significance of paracardiac lymph nodes enlargement in ovarian cancer. Clin Radiol 52 (1997) 692-697
66. Coakley F.V., Choi P.H., Gougoutas C.A., et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 223 2 (2002) 495-499
67. Pannu H.K., Horton K.M., and Fishman E.K. Thin section dual-phase multidetector-row computed tomography detection of peritoneal metastases in gynecologic cancers. J Comput Assist Tomogr 27 3 (2003) 333-340
68. Tempany C.M., Zou K.H., Silverman S.G., et al. Staging of advanced ovarian cancer: comparison of imaging modalities-report from the Radiological Diagnostic Oncology Group. Radiology 215 3 (2000) 761-767
69. Ricke J., Sehouli J., Hach C., et al. Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol 13 5 (2003) 943-949
70. Yoshida Y., Kurokawa T., Kawahara K., et al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR Am J Roentgenol 182 1 (2004) 227-233
71. Hubner K.F., McDonald T.W., Niethammer J.G., et al. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG). Gynecol Oncol 51 (1993) 197-204
72. Schroder W., Zimny M., Rudlowski C., et al. The role of 18-F-fluorodeoxyglucose position imaging tomography 18-F-FGD PET in ovarian carcinoma. Int J Gynecol Cancer 9 2 (1999) 117-122
73. Rose P.G., Faulhaber P., Miraldi F., et al. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 82 1 (2001) 17-21
74. Drieskens O., Stroobants S., Gysen M., et al. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer. Gynecol Obstet Invest 55 3 (2003) 130-134
75. Turlakow A., Yeung H.W., Salmon A.S., et al. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med 44 9 (2003) 1407-1412
76. Byrom J., Widjaja E., Redman C.W., et al. Can pre-operative computed tomography predict resectability of ovarian carcinoma at primary laparotomy?. Br J Obstet Gynaecol 109 4 (2002) 369-375
77. Qayyum A., Coakley F.V., Westphalen A.C., et al. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 96 2 (2005) 301-306
78. Woodward P.J., Hosseinzadeh K., and Saenger J.S. From the archives of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation. Radiographics 24 1 (2004) 225-246
79. Dachman A.H., Visweswaran A., Battula R., et al. Role of chest CT in the follow-up of ovarian adenocarcinoma. AJR Am J Roentgenol 176 (2001) 701-705
80. Sella T., Rosenbaum E., Edelmann D.Z., et al. Value of chest CT scans in routine ovarian carcinoma follow-up. AJR Am J Roentgenol 177 (2001) 857-859
81. Bast R.C., Xu F.J., Yu Y.H., et al. CA 125: the past and the future. Int J Biol Markers 13 4 (1998) 179-187
82. Santillan A., Garg R., Zahurak M.L., et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 23 36 (2005) 9338-9343
83. Wilder J.L., Pavlik E., Straughn J.M., et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol 89 2 (2003) 233-235
84. Park C.M., Kim S.H., Kim S.H., et al. Recurrent ovarian malignancy: patterns and spectrum of imaging findings. Abdom Imaging 28 3 (2003) 404-415
85. Chen L.M., and Karlan B.Y. Recurrent ovarian carcinoma: is there a place for surgery?. Semin Surg Oncol 19 1 (2000) 62-68
86. Low R.N., Duggan B., Barone R.M., et al. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year. Radiology 235 3 (2005) 918-926
87. Smith G.T., Hubner K.F., McDonald T., et al. Cost analysis of FDG PET for managing patients with ovarian cancer. Clin Positron Imaging 2 2 (1999) 63-70
88. Kim S., Chung J.K., Kang S.B., et al. [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. Eur J Nucl Med Mol Imaging 31 2 (2004) 196-201
89. Delbeke D., and Martin W.H. Positron emission tomography imaging in oncology. Radiol Clin North Am 39 5 (2001) 883-917
90. Nanni C., Rubello D., Farsad M., et al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol 31 7 (2005) 792-797
91. Sironi S., Messa C., Mangili G., et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 233 2 (2004) 433-440
92. Kubik-Huch R.A., Dorffler W., von Schulthess G.K., et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 10 5 (2000) 761-767
93. Murakami M., Miyamoto T., Lida T., et al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer 16 Suppl 1 (2006) 99-107
94. Pannu H.K., Bristow R.E., Cohade C., et al. PET-CT in recurrent ovarian cancer: initial observations. Radiographics 24 1 (2004) 209-223
95. Torizuka T., Nobezawa S., Kanno T., et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose. Eur J Nucl Med Mol Imaging 29 6 (2002) 797-803
96. Picchio M., Sironi S., Messa C., et al. Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment. Q J Nucl Med 47 2 (2003) 77-84
97. Barranger E., Kerrou K., Petegnief Y., et al. Laparoscopic resection of occult metastasis using the combination of FDG-positron emission tomography/computed tomography image fusion with intraoperative probe guidance in a woman with recurrent ovarian cancer. Gynecol Oncol 96 1 (2005) 241-244